1E11 is a humanized monoclonal antibody that recognizes a different epitope on the IV domain on the HER2 molecule than trastuzumab that was tested in gastric cancer and presented synergistic effects in combination with trastuzumab [34], but it has not been tested in breast cancer patients. Here, ERBB2 is linked to breast cancer.